Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Pepin

Nephrology Council Bluffs, IA Medical Doctor

NPI 1073995973 CMS profile 1373955

103 North Ave Ste 8, Council Bluffs, IA 51503

Open in the dashboard

General payments

$42,158

274 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Pepin of Council Bluffs, IA is reported in the CMS Open Payments database as having received $42,158 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,412 90
2024 General $11,104 51
2023 General $3,712 56
2022 General $2,929 38
2021 General $2,676 35
2020 General $91 1
2019 General $233 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Pepin
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Jeremy Pepin were reported at $21,412. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Jeremy Pepin Nephrology median Middle half National median
2019 $233 $236 $90–$588 $163
2020 $91 $135 $46–$364 $114
2021 $2,676 $202 $67–$551 $132
2022 $2,929 $242 $77–$695 $149
2023 $3,712 $254 $84–$766 $160
2024 $11,104 $300 $99–$852 $164
2025 $21,412 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $25,932 48 payments
  2. Bard Peripheral Vascular, Inc. $5,661 73 payments
  3. Medtronic, Inc. $4,082 32 payments
  4. Vantive US Healthcare LLC $2,506 18 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $2,076 48 payments
  6. Baxter Healthcare $623 10 payments
  7. Mozarc Medical US LLC $262 5 payments
  8. Relypsa, Inc. $177 4 payments
  9. ANI Pharmaceuticals, Inc. $125 1 payment
  10. NxStage Medical, Inc. $115 1 payment
  11. Other $599 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,936 13 payments
  2. Travel and Lodging $12,153 42 payments
  3. Food and Beverage $8,049 218 payments
  4. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. LOKELMA $18,625 20 payments
  2. FARXIGA $7,096 24 payments
  3. Kerendia $2,076 48 payments
  4. ELLIPSYS VASCULAR ACCESS SYSTEM $1,852 18 payments
  5. Renal - Chronic $1,442 9 payments
  6. Ellipsys $943 9 payments
  7. Renal - Acute $911 7 payments
  8. Renal - PD $639 10 payments
  9. COVERA $577 4 payments
  10. Crosser iQ $187 1 payment
  11. Other $2,481 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,095

Median for Nephrology: 954

Drug cost

$656,155

Median for Nephrology: $127,050

Branded share of claims

36%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 400 $293,509
Kerendia Finerenone Brand 163 $137,788
Xphozah Tenapanor Hcl Brand 18 $79,309
Ozempic Semaglutide Brand 39 $46,944
Lokelma Sodium Zirconium Cyclosilicate Brand 13 $16,688
Prosol Parenteral Amino Acid 20% No.1 Brand 88 $15,305
Jardiance Empagliflozin Brand 20 $14,998
Mounjaro Tirzepatide Brand 13 $12,662
Cinacalcet Hcl Generic 29 $9,863
Sevelamer Carbonate Generic 55 $9,255

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$154,724

Medicare's payments for the services billed

Medicare patients

285

Average age 74

Services billed

1,077

168 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 56%
Arthritis 46%
Heart failure 40%
Ischemic heart disease 39%
Depression 33%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $6,845
$6,845 400 —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $3,222
$3,222 13 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $221
$221 163 —
Ozempic
  • Novo Nordisk Inc $50
$50 39 —
JARDIANCE
  • Lilly USA, LLC $45
$45 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record